A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
In this prospective, single-center, randomized, placebo-controlled, double-blind clinical
trial, parturients with primary PPH are eligible for treatment with fibrinogen concentrate
following both vaginal delivery and cesarean section complicated by an estimated blood loss
(EBL) >1000 mL and an ongoing bleeding notwithstanding standard treatment measures (volume
replacement, uterine massage, and uterotonic agents).